Disease · MONDO_0043479
adenoviridae infectious disease
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. adenoviridae infectious disease. Diseases, record MONDO_0043479. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0043479
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- Adenoviridae caused disease or disorder, Adenoviridae disease or disorder, adenovirus infection, disease due to adenovirus
- Open Targets
Drugs6
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| BRINCIDOFOVIR | CHEMBL203321 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| BETAMETHASONE | CHEMBL632 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CIDOFOVIR | CHEMBL5314375 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| POSOLEUCEL | CHEMBL4594340 | Cell | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ACETAMINOPHEN | CHEMBL112 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DIPHENHYDRAMINE | CHEMBL657 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets6
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| FAAH | Fatty-acid amide hydrolase 1 | 1 | Anandamide amidohydrolase inhibitor | Phase 1 | https://conductscience.org/library/genes/2166 | Drugs and targets |
| HRH1 | Histamine H1 receptor | 1 | Histamine H1 receptor antagonist | Phase 1 | https://conductscience.org/library/genes/3269 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 1 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| PTGS1 | Cyclooxygenase | 1 | Cyclooxygenase inhibitor | Phase 1 | https://conductscience.org/library/genes/5742 | Drugs and targets |
| PTGS2 | Cyclooxygenase | 1 | Cyclooxygenase inhibitor | Phase 1 | https://conductscience.org/library/genes/5743 | Drugs and targets |
| TRPV1 | Transient receptor potential cation channel subfamily V member 1 | 1 | Vanilloid receptor opener | Phase 1 | https://conductscience.org/library/genes/7442 | Drugs and targets |
Trials8
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02087306 | Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early Versus Late Adenovirus Infection | Phase 3 | 201 | 2021-08-13 | Adenovirus Infection | BRINCIDOFOVIR | Its record names the disease | ClinicalTrials.gov |
| NCT05179057 | Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation | Phase 3 | 57 | 2024-05-08 | Adenovirus Infection | POSOLEUCEL | Its record names the disease | ClinicalTrials.gov |
| NCT03339401 | The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation | Phase 2 | 29 | 2021-01-25 | Adenovirus | BRINCIDOFOVIR | Its record names the disease | ClinicalTrials.gov |
| NCT07387367 | A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT | Phase 3 | 180 | Adenovirus Infections | BRINCIDOFOVIR, CIDOFOVIR | Its record names the disease | ClinicalTrials.gov | |
| NCT06299813 | Effectiveness of a Single Dose of Betamethasone in Children With Symptomatic Adenovirus Infection | Phase 3 | 80 | Adenovirus | BETAMETHASONE | Its record names the disease | ClinicalTrials.gov | |
| NCT04706923 | A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection | Phase 2 | 53 | Adenovirus Infections, Cytomegalovirus Infection | BRINCIDOFOVIR | Its record names the disease | ClinicalTrials.gov | |
| NCT01070797 | Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE) | Phase 1 | 10 | Adenovirus Infection, Epstein-Barr Virus Infections, Cytomegalovirus Infections, Stem Cell Transplant | ACETAMINOPHEN, DIPHENHYDRAMINE | Its record names the disease | ClinicalTrials.gov | |
| NCT02596997 | Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease | Adenovirus | BRINCIDOFOVIR | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials4
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Pediatric vs Adult: serious adverse events | 93 of 130 | 58 of 71 | 201 | NCT02087306 | Trial comparisons |
| Posoleucel, Then Placebo vs Placebo, Then Posoleucel: Number of Participants With Undetectable Adenovirus Infection | 11 of 25 | 9 of 21 | 46 | NCT05179057 | Trial comparisons |
| Brincidofovir vs Standard of Care: deaths from any cause | 4 of 20 | 1 of 9 | 29 | NCT03339401 | Trial comparisons |
| Brincidofovir vs Standard of Care: serious adverse events | 15 of 20 | 6 of 9 | 29 | NCT03339401 | Trial comparisons |
Papers from its trials2
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0043479
GET https://conductscience.org/api/diseases/v1/MONDO_0043479/drugs